ArticleCell death & disease2026
SUMOylation activates ECHS1 for adaptive catabolism in lung cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Cellular metabolism dynamically adapts to nutrient fluctuations, yet the regulatory mechanisms underlying this plasticity remain incompletely understood. In particular, the adaptive activation mechanism of enoyl-CoA hydratase short-chain 1 (ECHS1), a key mitochondrial enzyme for fatty acid and amino acid catabolism, is poorly characterized. Herein, we identify SUMO1 modification at lysine 128 of ECHS1 as an essential activation switch that drives mitochondrial catabolism and restricts growth of lung cancer cells. Nutrients generating crotonyl-CoA (fatty acids, lysine, tryptophan) stimulate this modification, accelerating crotonyl-CoA oxidation to acetyl-CoA. This metabolic adaptation decreases crotonyl-CoA pools, thereby reducing histone crotonylation (e.g., H2BK20cr and H3K27cr). Conversely, SUMOylation deficiency impairs formation of the catalytic ECHS1 homohexamer, increasing crotonyl-CoA accumulation and histone crotonylation. This epigenetically suppresses oxidative phosphorylation and associated ROS generation while activating PI3K-Akt signaling, promoting lung cancer growth in vitro and in vivo. In lung adenocarcinoma patients, H2BK20cr and H3K27cr levels are elevated in tumor tissues and predict poor survival, highlighting their clinical prognostic significance. Collectively, these findings establish ECHS1 SUMOylation as a nutrient-sensitive activation mechanism for adaptive catabolism and reveal mitochondrial SUMOylation as a critical regulator of nuclear epigenetic reprogramming, defining a metabolite-driven paradigm in cancer epigenetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.